Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roundhill Magnificent Seven ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Roundhill Magnificent Seven ETF trades at $65.67. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | MAGS | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $70.94 |
52-Week Low | $10.24 | $55.02 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MAGS (Roundhill Magnificent Seven ETF) trades at $66.28, up 1.81% on the day, with a bullish technical signal driven by moving averages. The ETF holds seven mega-cap tech stocks equally weighted, rebalanced quarterly. Recent news highlights AI-driven market broadening and MAGS's historical outperformance, though 2026 has seen volatility with a drop from YTD highs near $71. RSI_6 at 72.47 suggests short-term overbought conditions.
Outlook: MAGS offers concentrated exposure to leading tech innovators with strong long-term growth potential, but faces risks from high concentration, valuation concerns, and macroeconomic sensitivity. Near-term resistance at $67–68 may cap gains unless earnings momentum accelerates. Diversification benefits are limited due to single-sector focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
